The Future of Monocoa Antibody Therapes

22sec Snip

00:00

Play full episode

Summary

Transcript

Episode notes

I feel like the future of monocoa antibody therapes could be a little bit unknown for us. I'm really interested to see what place they take in this sort of annals. When we read the history books of how this was tackled in the meantime. Hyde, thank you so much for for joining us this week. We hope you have a good virus free week come.

In the early days of the pandemic, researchers raced to identify the most potent antibodies produced by the immune system in response to SAR-COV-2 infection and produce them in bulk. The resulting ‘monoclonal antibodies’ have since been tested in a variety of settings as treatments for COVID-19.

But despite promising clinical trial results and several therapies having already been approved, antibody therapies have not yet played a large role in the fight against COVID-19. In this episode of Coronapod, we ask why.

News: COVID antibody treatments show promise for preventing severe disease

News: Antibody therapies could be a bridge to a coronavirus vaccine — but will the world benefit?

Subscribe to Nature Briefing, an unmissable daily round-up of science news, opinion and analysis free in your inbox every weekday.

Hosted on Acast. See acast.com/privacy for more information.